PCOS Clinical Trial
Official title:
Determining the Rapidity With Which Exogenous P Suppresses Daytime LH (GnRH) Pulse Frequency in Women During the Follicular Phase of the Menstrual Cycle
The rapidity with which progesterone (P) suppresses daytime lutenizing hormone (LH) (and by inference gonadotropin releasing hormone (GnRH)) pulse frequency is unknown. We propose to assess this further using a randomized, cross-over, placebo-controlled study. Ovulatory women will begin E2 patches on day 4-8 of the cycle, while women with PCOS will begin E2 patches either on day 4-8 of the cycle or at least 8 weeks post-menses. After 3 d of E2 administration, women will undergo a 24-h sampling study in the GCRC. Beginning at 2000 h, blood for LH, FSH, E2, P, and T will be obtained over a 24-h period. After 10 h of sampling, either oral micronized P (100 mg p.o.) suspension or placebo suspension will be administered (according to randomization). At the completion of sampling, E2 patches will be discontinued. During a subsequent menstrual cycle (or after at least 3 weeks in oligomenorrheic PCOS), subjects will undergo another GCRC study identical to the first (including pretreatment with E2) except that oral P will be exchanged for placebo or vice versa in accordance with the crossover design. We will assess the acute effects of progesterone on LH frequency, with secondary endpoints being mean LH, LH pulse amplitude, and mean follicle-stimulating hormone (FSH). We propose two primary hypotheses: (1) administration of P (at 0600 h) to normally cycling adult women during the follicular phase will result in a demonstrable suppression of daytime LH (and by inference GnRH) pulse frequency within 12 hours; (2) administration of P (at 0600 h) to women with PCOS will result in less suppression of daytime LH pulse frequency than in ovulatory women without PCOS. A secondary hypothesis is that augmentation of LH amplitude after P administration will be less in PCOS compared to normal controls.
Studies under this protocol will be performed in normally cycling women and in women with
PCOS from 18 to 35 years old. Criteria for PCOS will be (a) clinical and/or biochemical
evidence of hyperandrogenism, (b) oligomenorrhea, and (b) the absence of clinical or
biochemical evidence of other potential causes of hyperandrogenism and/or oligomenorrhea.
After informed consent is obtained, all potential subjects will undergo a screening history
and physical exam. Subjects will need to fast for a minimum of 8 hours prior to screening
blood draw. After informed consent is obtained, blood tests (~ 16 cc) will be drawn at
0800-0900 h as follows: LH, FSH, progesterone (P), estradiol (E2), total testosterone, SHBG,
17-OHP, androstenedione, DHEA-S, beta-hCG, TSH, prolactin, CBC, chemistry and liver panels,
hemoglobin A1c, fasting insulin, and fasting glucose. Additionally, BOD POD® will be used to
measure total fat mass, fat free mass, and percent body fat. Waist and hip circumference will
be measured.
This study follows a crossover design, with assessment of the acute effects of P and placebo
(individually) on GnRH pulse frequency; subjects will be randomized to receive either P or
placebo during the first GCRC admission, with subsequent GCRC study occurring during a
subsequent cycle.
Women will begin E2 patches (0.1 mg/d per patch, 2 patches [delivering a total of 0.2 mg/d]
placed on the abdomen and changed every 2 d) on the evening of day 4-8 of the study cycle
(controls or PCOS) or >= 8 weeks post-menses (PCOS only). These patches will be continued for
a total of 4 d, with GCRC admission occurring on day 3 of E2 administration. Exogenous E2
administration will standardize hypothalamic exposure to E2 and help ensure the presence of
sufficient hypothalamic P receptors.
Four to 5 days before a scheduled GCRC admission, subjects will come to the GCRC for an
outpatient blood draw for P and beta-HCG (2 cc). If 30 days will have elapsed between (a) the
most recent hemoglobin and hematocrit and (b) the scheduled GCRC admission, a hemoglobin and
hematocrit will also be drawn at this time (1cc).
After 3 d of E2 administration, women will undergo a 24-h sampling study in the GCRC.
Estradiol administration (E2 patches) will continue throughout the GCRC admission. Subjects
will be admitted to the GCRC at 1800 h (2 h prior to sampling). Beginning at 2000 h, blood
will be obtained through an indwelling i.v. forearm heparin lock over a 24-h period as
follows: LH every 10 min (1 ml); P every 30 min (1 ml); FSH, E2, and T every 2 h (assays to
be run in same samples as LH and P). SHBG, fasting insulin, and fasting glucose (i.e.,
fasting since 2200 h) will be run on the 0600 h sample (extra 2 cc drawn). (Subjects will
fast from 2200 to 0600 h.) After 10 h of sampling (i.e., at 0600 h), either oral micronized P
(100 mg p.o.) suspension or placebo suspension will be administered (according to
randomization). With exogenous P, we aim to achieve mean plasma P concentrations 4-8 ng/ml.
Subjects will not be allowed to sleep during the day (i.e., from 0600 to 2200 h). Subjects
will be encouraged to sleep from 2200 to 0600. Sleep will be formally evaluated
(extraoculograms, electroencephalograms, wrist actigraphy, etc.). At the completion of
sampling, E2 patches will be discontinued. Volunteers will be discharged on oral iron (325 mg
BID). We will ask women to eat only the food provided by the GCRC.
Subjects will undergo another GCRC study identical to the first (including pretreatment with
E2, outpatient blood draw 4-5 days before admission, etc.), except that oral P will be
exchanged for placebo or vice versa in accordance with the crossover design. (Subjects will
again begin E2 patches on the evening of cycle day 4-8 [controls or PCOS] or >= 8 weeks
post-menses [PCOS only].) In this way, we will be able to standardize any change in GnRH
pulse frequency after P administration to any change in GnRH pulse frequency after placebo
administration.
The study will end after the second GCRC admission. Subjects will be asked to continue oral
iron supplementation for at least 30 d after this last GCRC admission.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06101147 -
Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome
|
Phase 2 | |
Completed |
NCT02037672 -
PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome
|
Phase 4 | |
Completed |
NCT01833949 -
Unilateral Laparoscopic Diathermy Adjusted to Ovarian Volume
|
N/A | |
Completed |
NCT03608813 -
Myo-inositol, D-chiro-inositol and Glucomannan in PCOS
|
||
Not yet recruiting |
NCT05298657 -
The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment
|
||
Completed |
NCT05951309 -
Myoinositol Treatment and Asprosin Levels in PCOS
|
N/A | |
Enrolling by invitation |
NCT04485403 -
The Effect of Ibuprofen on Women With PCOS.
|
Phase 2 | |
Not yet recruiting |
NCT03978013 -
Pomegranate Juice Effect on Oxidative Stress in Infertile Women During IVF Treatment
|
N/A | |
Recruiting |
NCT03767569 -
Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients
|
Phase 3 | |
Completed |
NCT05843955 -
Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome
|
||
Recruiting |
NCT05971849 -
Dampening the Reproductive Axis With Continuous Kisspeptin
|
Phase 1 | |
Recruiting |
NCT04597099 -
Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion
|
Early Phase 1 | |
Active, not recruiting |
NCT05206448 -
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
|
Phase 4 | |
Recruiting |
NCT02358421 -
Prediction of High Ovarian Response After Assisted Reproductive Techniques
|
N/A | |
Completed |
NCT04113889 -
Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome
|
Phase 2 | |
Completed |
NCT04562883 -
Single vs. Group CAPA-IVM Culture of Cumulus-oocyte Complexes
|
N/A | |
Recruiting |
NCT03264638 -
A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS
|
Phase 2 | |
Recruiting |
NCT02024984 -
Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial
|
Phase 1 | |
Completed |
NCT01709942 -
Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)
|
Phase 3 | |
Completed |
NCT01911468 -
Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin
|
Phase 4 |